MORRISVILLE —Heat Biologics, Inc., an immunotherapy-focused biotechnology company, announced on Sunday that its chief scientific and operating officer, Jeff T. Hutchins, Ph.D., will be leaving the company at the end of the year, according to an 8-K filing.
Hutchins joined Heat Biologics in January 2017 as its chief scientific officer and senior vice president of preclinical development. He was named chief operating officer in July 2017.
The executive’s four-year employment agreement expires on Dec. 31.
The 8-K filing can be found here.
Heat Biologics (HTBX) shares were last trading down 3.33 percent, or four cents, near $1.16.
This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism
